Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA3 | P07451 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA6 | P23280 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457761 | 1.00 | HCAR2 (0.59) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL2375512 | 0.85 | HCAR2 (0.55) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL8921111 | 0.83 | TBXAS1 (0.68) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL14081549 | 0.82 | HCAR2 (0.81) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL713717 | 0.82 | HCAR2 (0.81) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL68395 | 0.82 | HCAR2 (0.81) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL4307999 | 0.82 | HCAR2 (0.66) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL2300813 | 0.82 | HCAR2 (0.61) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL27698116 | 0.82 | HCAR2 (0.61) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL2300815 | 0.82 | HCAR2 (0.61) | HCAR2ESR1ESR2CA12AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2069291-A1 | HDAC INHIBITORS | Chroma Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HCAR2 283/4885ESR1 921/4885ESR2 669/4885 |
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HCAR2 279/4885ESR1 908/4885ESR2 681/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | HCAR2 502/4885ESR1 1047/4885ESR2 516/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HCAR2 283/4885ESR1 921/4885ESR2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.